# Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers

> **NCT01784536** · PHASE1 · COMPLETED · sponsor: **Melinta Therapeutics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Single-Dose IV Oritavancin Diphosphate

## Key facts

- **NCT ID:** NCT01784536
- **Lead sponsor:** Melinta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01784536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01784536, "Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01784536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*